Last reviewed · How we verify

NCT01615861

Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens

Completed NA Last updated 14 November 2019
What this trial tests

NA trial testing IOL implantation in Cataract in 103 participants. Completed in 16 June 2015.

Timeline
8 November 2012
Primary endpoint
16 June 2015
16 June 2015

Quick facts

Lead sponsorBausch & Lomb Incorporated
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment103
Start date8 November 2012
Primary completion16 June 2015
Estimated completion16 June 2015
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

40 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate clinical outcomes following sub-2 mm micro-incision cataract surgery (MICS) and intraocular lens (IOL) implantation. This study is evaluated in two Phases * V4 (6M) endpoint: primary analysis * V5 (12M) and V6 (34M): EPCO score and Nd Yag incidence analysis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of IOL implantation

Trials testing the same drug.

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01615861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing